ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, C. Sessa, Andreas du Bois, +13

International Journal of Gynecological Cancer

Borderline TumoursTumoral PathologyMedicinePathologyGynecology +7

Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

Aarón Sulkes, Joan A. Smyth, C. Sessa, +7

British Journal of Cancer

Gastrointestinal OncologyAdvanced Gastric CancerMedicineCancer ManagementGastroenterology +7

European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery

Denis Querleu, François Planchamp, Luis Chiva, +18

International Journal of Gynecological Cancer

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Nicoletta Colombo, Michele Peiretti, Gabriella Parma, +5

Annals of Oncology

Gynecological SurgeryMedicineCancer ManagementEpithelial Ovarian CarcinomaGynecology +4

Activity of docetaxel (Taxotere) in small cell lung cancer

J F Smyth, I E Smith, C. Sessa, +4

European Journal of Cancer

MedicinePharmacologyAnti-cancer AgentOncologyLung Cancer +1

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, +15

Targeted Oncology

Parp Inhibitor OlaparibPharmacological StudyMedicineTablet FormulationPharmacotherapy +5

Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy

Aron Goldhirsch, Richard Greiner, E. Dreher, +13

Cancer

Surgical OncologyCancer ManagementGynecologyWhole-abdominal RadiotherapySurgery +14

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial

A Roth, Rudolf Maibach, Nicola Fazio, +7

Annals of Oncology

Full-dose DocetaxelOncologyGastrointestinal OncologyMedicineAdvanced Gastric Carcinoma +8

The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

DavidR. Newell, C. Sessa, S.J. Harland, +3

Cancer Chemotherapy and Pharmacology

Cb 3717Medicinal ChemistryPharmacological StudyBiochemistryMedicine +8

Update on PARP1 inhibitors in ovarian cancer

C. Sessa

Annals of Oncology

MedicineGynecologyParp1 InhibitorsAnti-cancer AgentCancer Treatment +3